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Abstract
Background: We sought to describe targeted DNA sequencing data of persistent/
recurrent laryngeal squamous cell carcinoma (LSCC) and to compare gene-specific
alteration frequencies with that of primary, untreated LSCC specimens from The
Cancer Genome Atlas (TCGA).
Methods: The tumors of 21 patients with persistent/recurrent LSCC were subjected
to targeted DNA sequencing using the Ion AmpliSeq Comprehensive Cancer
Panel. Gene-specific alteration frequencies were compared (Chi-Square test) to pri-
mary, untreated LSCC sequencing data from TCGA using the cBioPortal platform.
Results: Persistent/recurrent LSCC was characterized by a high rate of inactivating
alterations in TP53 (38.1%) and CDKN2A (33%), amplification events of CCND1
(19.1%), and ERBB2 (14.3%), and NOTCH1 (19.1%) mutations. Comparison of
primary vs persistent/recurrent LSCC revealed significant differences in alter-
ation frequencies of eight critical genes: BAP1, CDKN2A, DCUN1D1, MSH2,
MTOR, PIK3CA, TET2, and TP53.
Conclusions: Our results provide preliminary support for a distinct mutational pro-
file of persistent/recurrent LSCC that requires validation in larger cohorts.
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1 | INTRODUCTION
Laryngeal squamous cell carcinoma (LSCC) remains a signifi-
cant source of morbidity and mortality, with 4000 deaths annu-
ally in the United States.1 Organ preservation radiotherapy
This study was presented as a poster at the 2018 Multidisciplinary Head and
Neck Cancers Symposium, Scottsdale, AZ (February 15-February
17, 2018).
Received: 22 April 2018 Revised: 22 June 2018 Accepted: 6 September 2018
DOI: 10.1002/hed.25444
Head & Neck. 2019;41:423–428. wileyonlinelibrary.com/journal/hed © 2018 Wiley Periodicals, Inc. 423
(RT) and chemoradiotherapy (CRT) have become standard of
care for many primary LSCC. However, disease recurrence
remains a difficult issue, with 5-year disease-free survival rates
for advanced LSCC after initial RT or CRT2 ranging from
30 to 60%.3,4 For patients with persistent/recurrent LSCC after
initial treatment, prognosis is guarded.5–7 Our best data on the
genomic landscape of LSCC comes from previously untreated
patients within The Cancer Genome Atlas (TCGA). Thus, a
better understanding of genetic drivers of persistent/recurrent
LSCC to provide prognostic biomarkers and targets for novel
therapeutics are needed in this patient cohort.8
Analysis of primary LSCC specimens in recent whole-
exome sequencing (WES) studies by Stransky et al. (n = 15)9
and the Cancer Genome Atlas Network (n = 117)10 has identi-
fied high rates of TP53mutations, activating PIK3CA alterations,
CCND1 and EGFR amplification, CDKN2A deletion, and
NOTCH1 aberrations in primary LSCC. ERBB2 amplification
has similarly emerged as a potential oncologic driver in a smaller
subset of LSCC.11 Importantly, these studies did not specifically
look into persistent/recurrent tumor mutational profiles after
RT/CRT.
The biology of recurrent head and neck squamous cell
carcinoma is not well characterized, though recent sequenc-
ing efforts have revealed unique, and occasionally target-
able, mutational signatures in a handful of these tumors.12,13
There is significant rationale for distinct mutational signa-
tures in recurrent LSCC given the poor initial clinical
response of these tumors, the potential for de novo mutations
due to RT/CRT, and tumor evolution and subclonal prolifer-
ation. As such, a better understanding of molecular alter-
ations underlying these cancers is paramount to advancing
precision oncology paradigms in this cohort.
We hypothesized that the mutational landscape in persistent/
recurrent LSCC will be distinct from primary, untreated LSCC.
Herein, we report mutational profiles of persistent/recurrent
LSCC in the largest patient cohort to date and illustrate impor-
tant differences in mutational rates of LSCC driver genes by
comparison to TCGA database of primary, untreated LSCC.
2 | PATIENTS AND METHODS
Our study used a convenient sample of patients with biopsy-
proven persistent/recurrent LSCC (n = 21) who were treated
at the University of Michigan Hospital and Health Systems
between 2000 and 2012. Clinical (eg, demographics, tobacco
and alcohol history, tumor sub-site, American Joint Commit-
tee on Cancer [AJCC] stage, and treatment) and survival
data were collected and summarized.
Formalin-fixed, paraffin-embedded (FFPE) specimens
were obtained from the University of Michigan pathology
archive under an Institutional Review Board (IRB)-approved
protocol (HUM00080561). Tumor cores and adjacent nor-
mal tissue were taken from FFPE blocks, and genomic DNA
was isolated using the Qiagen Allprep DNA/RNA FFPE kit
(Qiagen, Hilden, Germany) and quantified using a Qubit as
previously described.14
Amplicon-based DNA sequencing of genes relevant to
LSCC biology was performed on the Ion Torrent Personal
Genome Machine, utilizing the Ion AmpliSeq Comprehen-
sive Cancer Panel (Thermo Fisher Scientific, Waltham, Mas-
sachusetts), as previously described.11,15 Single-nucleotide
variants (SNVs) and indels were called using the Torrent
Variant Caller, annotated using ANNOVAR, and filtered for
candidate non-synonymous somatic variants.16 Gene-level
copy number variants (CNV) were determined by taking the
mean of the coverage-weighted per-probe ratios, as
described.17 As per the manufacturer's specifications, the Ion
AmpliSeq Comprehensive Cancer Panel yields ≥94% exome
sequencing coverage at an average read depth of 350×.11,15
WES data of primary LSCC (n = 117) specimens was
retrieved from the TCGA provisional dataset using the cBio-
Portal platform.18,19 Chi-Square test (α = 0.05) using
GraphPad Prism (GraphPad Software, La Jolla, California)
was used for comparison of mutational rates in persistent/
recurrent vs primary LSCC.
3 | RESULTS
Clinical characteristics of the cohort are summarized in
Table 1. All included patients were male with significant
tobacco use history. The mean (range) age of included
patients at diagnosis was 59 (40-77) years. Early- and late-
stage initial tumors were equally represented in our cohort.
Primary treatment consisted of CRT (n = 10), RT (n = 9),
and partial or total laryngectomy with adjuvant RT (n = 2).
The mean (range) disease-free interval (DFI) was 29 (3-150)
months. Sites of LSCC recurrence included local (n = 18),
regional (n = 1), local and distant (n = 1), and distant
(n = 1). Despite surgical salvage in 17 (81%) patients,
9 (43%) died of LSCC.
Targeted DNA sequencing of persistent/recurrent LSCC
specimens revealed a high frequency of alterations also pre-
sent in primary LSCC, including inactivating TP53 (38.1%)
and CDKN2A (33%) mutations and complex NOTCH1
(19.1%) alterations (Figure 1). Potentially targetable amplifi-
cations of CCND1 (19.1%), ERBB2 (14.3%), and PIK3CA
(9.5%) were also seen. Our modest sample size precludes
definitive statistical analyses of the effect of specific genetic
alterations on survival in our cohort. However, we are able
to highlight mutational profiles of individual patients with
persistent/recurrent LSCC who recurred and ultimately died
of disease, thus nominating such genetic alterations for fur-
ther study and potential therapeutic targeting.
Patient number 4 recurred locally 28 months after CRT
for stage III primary disease, ultimately dying of recurrent
LSCC 16 months after salvage laryngectomy. His recurrent
tumor harbored missense mutations in BRCA2 and MSH2.
Patient number 6 experienced a late, unresectable local
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recurrence, 63 months after CRT for stage IV disease, and ulti-
mately died 4 months later. His recurrent tumor was character-
ized by CDKN2A deletion and amplification of PIK3CA and
SOX2. Patient number 10 recurred locally 13 months after RT
for stage I disease and died of recurrent disease 1 year after sal-
vage laryngectomy. His recurrent LSCC harbored nonsense
NOTCH1 alteration and TP53 missense mutation. Finally,
patient number 14 recurred distantly 4 months after CRT for
stage IV disease, dying 3 months after initiation of palliative
RT. His tumor harbored multiple deleterious alterations, includ-
ing inactivating missense mutations in ATM, NOTCH1, and
TP53, as well as ERBB2 amplification and CDKN2A deletion.
We next compared the alteration frequency of 52 genes in
the Ion AmpliSeq Comprehensive Cancer Panel between our
persistent/recurrent LSCC cohort and the primary, untreated
TCGA cohort (n = 117) (Figure 2, Supporting Information
Table S1). Primary LSCC harbored a significantly higher rate
of characteristic CDKN2A, PIK3CA, and TP53 alterations.
Amplification of DCUN1D1, a candidate oncogene at the 3q
chromosomal locus implicated in squamous cell carcinogene-
sis, was also seen more frequently in primary LSCC (Figure 2).20
Conversely, the PI3K pathway effector MTOR, the critical
DNA mismatch repair geneMSH2, and the BRCA1-associated
protein BAP1 harbored complex mutational patterns at a
higher frequency in persistent/recurrent LSCC.
4 | DISCUSSION
Disease recurrence after definitive initial treatment for LSCC
is a therapeutic challenge due to constraints imparted by pre-
vious therapies, considerable morbidity of salvage surgery,
and potential acquired resistance of disease to chemotherapy
and radiation. Prognosis for recurrent LSCC has stagnated
in recent decades, with median survival after recurrence
of 22 months for patients eligible for salvage surgery or re-
irradiation and less than 12 months in those administered pal-
liative chemotherapy.21 The complex genetic alterations driv-
ing LSCC recurrence, progression, and treatment resistance
need to be better characterized to guide development of preci-
sion therapeutics in the bench-to-bedside paradigm.
Biologically, cancer recurrence is preceded by a com-
plex, branched evolution of subclonal populations within the
primary tumor that persist under selective treatment pres-
sures and propagate with further accumulation of deleterious
mutations.22 Hedberg et al. performed WES of eight primary
tumor-metachronous recurrence pairs of head and neck squa-
mous cell carcinoma (HNSCC).12 The authors showed that
nearly 40% of somatic variants identified in the recurrent can-
cers were new and absent in the primary tumor, including
amplification of CCND1 and nonsynonymous mutations of
DDR2 (discoidin domain receptor tyrosine kinase 2). DDR2
TABLE 1 Clinical characteristics of patients with persistent/recurrent LSCC
Patient no. Sex Age
Smoking
status
Pack
years
Primary
stage
Initial
treatment
Recurrence
site DFI (months)
Recurrence
treatment
Survival
monthsa
Died of
disease
1 M 72 Former 40 III CRT Larynx 10 Surgery 104 No
2 M 48 Current 70 IV RT Larynx 4 Surgery 37 No
3 M 64 Former 120 II CRT Larynx 21 Surgery 87 No
4 M 62 Former 20 III CRT Larynx 28 Surgery 16 Yes
5 M 59 Current 80 IV Surgery Neoglottis, lung 118 Surgeryb 102 No
6 M 68 Former 20 IV CRT Larynx 63 None 4 Yes
7 M 65 Former 63 I RT Larynx 9 Surgery 98 No
8 M 52 Former 50 IV CRT Larynx 10 Surgery 67 Yes
9 M 68 Current 80 II CRT Larynx 4 Surgery 9 No
10 M 58 Current 30 I RT Larynx 13 Surgery 12 Yes
11 M 40 Current 20 II RT Larynx 71 Surgery 55 No
12 M 52 Current 40 IV CRT Tongue Base 50 Surgery 7 Yes
13 M 57 Former 40 II RT Larynx 3 Surgery 114 No
14 M 61 Current 45 IV CRT Diffuse 4 Palliative RT 3 Yes
15 M 63 Former 180 IV CRT Larynx 9 Surgery 80 No
16 M 75 Former 30 I RT Larynx 16 Surgery 52 No
17 M 50 Former 30 III RT Larynx 3 Surgery 10 No
18 M 53 Current 35 IV CRT Neck 9 Surgery 6 Yes
19 M 51 Former 35 I RT Larynx 10 Surgery 88 No
20 M 43 Current 20 II Surgery Larynx 150 RT 44 Yes
21 M 77 Former 30 I RT Larynx 8 Surgery 44 Yes
Abbreviations: CRT, chemoradiotherapy; DFI, disease-free interval; LSCC, laryngeal squamous cell carcinoma; RT, radiotherapy.
a Time from date of recurrence to most recent clinical follow-up or death from any cause.
b Patient underwent salvage laryngectomy and thoracoscopic wedge resection of solitary lung metastasis.
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alterations promote cellular migration, invasion, and metastasis
in HNSCC23 and confer sensitivity to the SRC-family kinase
inhibitor dasatinib in other cancers.24 Implementation of routine
sequencing panels in persistent/recurrent LSCC management
may therefore exploit unique biology of tumor recurrence and
nominate novel therapeutic options in this patient cohort.
To date, ours is the largest targeted sequencing cohort of
persistent/recurrent LSCC, allowing for comparison to primary
LSCC mutational profiles and nomination of specific genetic
aberrations for further study. Because of our modest sample
size, we were unable to derive statistical models for predicting
survival outcomes in persistent/recurrent LSCC on the basis of
specific genetic perturbations. However, it is evident that the
recurrent tumors of patients with particularly poor outcomes
harbor multiple complex, and potentially targetable, genomic
alterations that are attractive candidates for further study.
Surprisingly, we found higher rates of deleterious alterations
in CDKN2A, PIK3CA, and TP53 in primary, untreated LSCC
(Figure 2). One possibility for this observation is the existence
of a sampling bias within our cohort such that alteration fre-
quencies for these crucial genes in persistent/recurrent LSCC
are falsely lowered. These findings require validation in larger
FIGURE 1 Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma (LSCC). Each column represents one patient/sequenced tumor.
Genes altered in ≥1 patient/sequenced tumor shown [Color figure can be viewed at wileyonlinelibrary.com]
FIGURE 2 Frequency of alterations in eight critical genes differs in primary
vs persistent/recurrent laryngeal squamous cell carcinoma (LSCC). P-value for
comparison (Chi-square) listed above each gene [Color figure can be viewed at
wileyonlinelibrary.com]
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sequencing cohorts. However, our preliminary data suggest that
LSCC recurrence and progression may rely on more complex,
alternative patterns of dysregulation in cellular growth and cell-
cycle control pathways relative to primary LSCC. This unique
pathogenetic complexity of persistent/recurrent LSCC likely
manifests clinically as resistance to conventional chemotherapy
and targeted agents and disease progression and early mortality.
The histone modifier BAP1 and the DNA mismatch repair
gene MSH2 were both more frequently altered in persistent/
recurrent LSCC. BAP1 was recently shown to induce resistance
to RT in HNSCC by modulating homologous recombination
mechanisms.25 Defects in MSH2 promote microsatellite insta-
bility and accumulation of deleterious mutations by interference
with nucleotide mismatch repair processes.26 Aberrations in cel-
lular DNA damage repair pathways may therefore be central to
pathogenesis of persistent/recurrent LSCC and are attractive tar-
gets for potential therapeutic modulation.
Ultimately, confirmation of unique mutational profiles of
primary vs persistent/recurrent LSCC suggested by our study
and other authors is needed in larger cohorts. Similarly, how
genomic aberrations in LSCC interact with other aspects of
tumor biology (eg, immune microenvironment) to promote
disease recurrence and progression requires further elucida-
tion to improve outcomes in this population.27
Our study has several limitations worth noting. Our per-
sistent/recurrent LSCC samples were sequenced from FFPE
on a targeted exome, commercially available sequencing
platform. This is in contrast to TCGA, which used whole-
genome sequencing and WES of fresh-frozen primary
tumors. Our comparison of mutational rates in primary vs
persistent/recurrent LSCC needs to be interpreted in this
light. However, several recent studies have demonstrated high
(ie, > 90%) concordance rates in detection of SNVs and
CNVs in coding genomic regions between matched fresh-
frozen and FFPE tumor samples.28–30 In addition, comparison
of amplicon-based, targeted exome sequencing to TCGA
dataset is a well-established practice in the HNSCC litera-
ture.11,13 Thus, we believe that these differences in DNA
sequencing methodology do not significantly diminish the
validity of our comparisons and conclusions. Second, the rela-
tively small number of persistent/recurrent LSCC samples in
our study limits our ability to draw sophisticated statistical
conclusions regarding the impact of specific genomic alter-
ations on survival in persistent/recurrent LSCC. Finally, due
to limited availability of archived tissue from our patients' pri-
mary tumors, we were unable to directly compare gene alter-
ation frequencies in primary vs persistent/recurrent LSCC
within individual patients.
Future studies should prioritize whole-exome and tran-
scriptomic profiling of larger patient cohorts enriched for
both locoregional and distant recurrences of LSCC to fully
capture the unique mutational profiles of persistent/recurrent
LSCC. As in Hedberg et al.,12 continued efforts to character-
ize pathogenetic mechanisms of disease recurrence by DNA
sequencing of matched primary and recurrent LSCC speci-
mens from individual patients is paramount.
5 | CONCLUSIONS
Targeted DNA sequencing of persistent/recurrent LSCC reveals
important differences in gene-specific alteration frequencies of
these tumors compared to primary, untreated LSCC from TCGA.
Our results provide preliminary support for a distinct mutational
profile of persistent/recurrent LSCC that requires confirmation in
larger cohorts. These data may be leveraged in future precision
oncology initiatives to inform patient and mutation-centric tar-
geted interventions in this patient population.31
ACKNOWLEDGMENTS
We thank C.J.L., D.H.H., A.K.C., and S.A.T. for technical
support.
ORCID
John Chad Brenner https://orcid.org/0000-0003-3238-1111
REFERENCES
1. Surveillance, Epidemiology, and End Results (SEER) Program – National
Cancer Institute. Cancer Stat Facts: Laryngeal Cancer. 2016. Accessed
February 6, 2018 from https://seer.cancer.gov/statfacts/html/laryn.html.
2. Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf G,
Fisher SG, et al. Induction chemotherapy plus radiation compared with sur-
gery plus radiation in patients with advanced laryngeal cancer. N Engl J
Med. 1991;324:1684-1690.
3. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG
91-11: a comparison of three nonsurgical treatment strategies to preserve the
larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;
31:845-852.
4. Denaro N, Russi EG, Lefebvre JL, Merlano MC. A systematic review of cur-
rent and emerging approaches in the field of larynx preservation. Radiother
Oncol. 2014;110:16-24.
5. Birkeland AC, Beesley L, Bellile E, Rosko AJ, et al. Predictors of survival
after total laryngectomy for recurrent/persistent laryngeal squamous cell car-
cinoma. Head Neck. 2017;39:2512-2518.
6. Brandstorp-Boesen J, Sorum Falk R, Boysen M, Brondbo K. Impact of
stage, management and recurrence on survival rates in laryngeal cancer.
PLoS One. 2017;12:e0179371.
7. Forastiere AA, Weber RS, Trotti A. Organ preservation for advanced larynx
cancer: issues and outcomes. J Clin Oncol. 2015;33:3262-3268.
8. Ludwig ML, Birkeland AC, Hoesli R, Swiecicki P, Spector ME,
Brenner JC. Changing the paradigm: the potential for targeted therapy in
laryngeal squamous cell carcinoma. Cancer Biol Med. 2016;13:87-100.
9. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head
and neck squamous cell carcinoma. Science. 2011;333:1157-1160.
10. The Cancer Genome Atlas Network. Comprehensive genomic characteriza-
tion of head and neck squamous cell carcinomas. Nature. 2015;517:
576-582.
11. Birkeland AC, Yanik M, Tillman BN, et al. Identification of targetable
ERBB2 aberrations in head and neck squamous cell carcinoma. JAMA Oto-
laryngol Head Neck Surg. 2016;142:559-567.
12. Hedberg ML, Goh G, Chiosea SI, et al. Genetic landscape of metastatic and
recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016;126:
169-180.
13. Morris LG, Chandramohan R, West L, et al. The molecular landscape of
recurrent and metastatic head and neck cancers: insights from a precision
oncology sequencing platform. JAMA Oncol. 2017;3:244-255.
SMITH ET AL. 427
14. Tillman BN, Yanik M, Birkeland AC, et al. Targeted sequencing of an epi-
demiologically low risk patient defines fibroblast growth factor family aber-
rations as a putative driver of head and neck squamous cell carcinoma. Head
Neck. 2016;38:1646-1652.
15. Warrick JI, Hovelson DH, Amin A, et al. Tumor evolution and progression
in multifocal and paired non-invasive/invasive urothelial carcinoma. Virch-
ows Arch. 2015;466:297-311.
16. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucleic Acids Res.
2010;38:e164.
17. Grasso C, Butler T, Rhodes K, et al. Assessing copy number alterations in
targeted, amplicon-based next-generation sequencing data. J Mol Diagn.
2015;17:53-63.
18. Cerami E, Gao J, Dogrusoz A, et al. The cBio cancer genomics portal: an
open platform for multidimensional cancer genomics data. Cancer Discov.
2012;2:401-404.
19. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer
genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;
6(269):pl1.
20. Sarkaria I, O-charoenrat P, Talbot SG, et al. Squamous cell carcinoma
related oncogene/DCUN1D1 is highly conserved and activated by amplifica-
tion in squamous cell carcinomas. Cancer Res. 2006;66:9437-9444.
21. Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG. Decision making
in the management of recurrent head and neck cancer. Head Neck. 2014;
36(1):144-151.
22. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and
branched evolution revealed by multiregion sequencing. N Engl J Med.
2012;366:883-892.
23. Xu J, Lu W, Zhang S, et al. Overexpression of DDR2 contributes to cell
invasion and migration in head and neck squamous cell carcinoma. Cancer
Biol Ther. 2014;15(5):612-622.
24. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase
gene identify a novel therapeutic target in squamous cell lung cancer. Can-
cer Discov. 2011;1:78-89.
25. Liu X, Kumar M, Yang L, et al. BAP1 is a novel target in HPV-negative
head and neck cancer. Clin Cancer Res. 2018;24(3):600-607.
26. Cortes-Ciriano I, Lee S, Park W, Kim T, Park P. A molecular portrait of
microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180.
27. Hoesli R, Birkeland AC, Rosko AJ, et al. Proportion of CD4 and CD8 tumor
infiltrating lymphocytes predicts survival in persistent/recurrent laryngeal
squamous cell carcinoma. Oral Oncol. 2018;77:83-89.
28. Robbe P, Popitsch N, Knight S, et al. Clinical whole-genome sequencing
from routine formalin-fixed, paraffin-embedded specimens: pilot study for
the 100,000 genomes project. Genet Med. 2018. Epub ahead of print 2018
Feb 1. https://doi.org/10.1038/gim.2017.241.
29. Hedegaard J, Thorsen K, Lund M, et al. Next-generation sequencing of RNA and
DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded
samples of human cancer and normal tissue. PLoS One. 2014;9(5):e98187.
30. Oh E, Choi Y, Kwon M, et al. Comparison of accuracy of whole-exome
sequencing with formalin-fixed paraffin-embedded and fresh frozen tissue
samples. PLoS One. 2015;10(12):e0144162.
31. Birkeland AC, Uhlmann WR, Brenner JC, Shuman AG. Getting personal:
head and neck cancer management in the era of genomic medicine. Head
Neck. 2016;38(S1):e2250-e2258.
SUPPORTING INFORMATION
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
How to cite this article: Smith JD, Birkeland AC,
Rosko AJ, et al. Mutational profiles of persistent/
recurrent laryngeal squamous cell carcinoma. Head &
Neck. 2019;41:423–428. https://doi.org/10.1002/hed.
25444
428 SMITH ET AL.
